CONBA(SH:600572) Zheng Quan Zhi Xing·2025-06-20 11:22Core Viewpoint - The legal opinion issued by Beijing Guantao (Hangzhou) Law Firm confirms that Zhejiang Kang En Bei Pharmaceutical Co., Ltd.'s differentiated dividend distribution plan for the year 2024 complies with relevant laws and regulations, ensuring no harm to the interests of the company and its shareholders [8]. Group 1: Differentiated Dividend Distribution - The differentiated dividend distribution is based on the company's net profit of RMB 405,473,540.71 for 2024, with a 10% legal surplus reserve of RMB 40,547,354.07 being deducted [6][7]. - The company plans to distribute a cash dividend of RMB 1.50 (including tax) for every 10 shares to all shareholders, calculated based on the total share capital after excluding the shares held in the repurchase account [6][7]. Group 2: Share Repurchase Details - The company announced a share repurchase plan with a total fund of no less than RMB 200 million and no more than RMB 400 million, with the repurchase period set for six months from the board's approval date [4][5]. - As of July 21, 2024, the company completed the repurchase of 63,579,048 shares, accounting for 2.47% of the total share capital, with an average repurchase price of RMB 4.72 per share [5][6]. Group 3: Legal Compliance and Conclusion - The law firm confirms that the differentiated dividend distribution adheres to the Company Law, Securities Law, and other relevant regulations, ensuring that it does not harm the interests of the company and its shareholders [8]. - The legal opinion is intended solely for the purpose of the differentiated dividend distribution and must not be used for any other purpose without prior written consent from the law firm [3].